The present study explored the treatment mechanism of metformin and found that metformin attenuated lupus symptoms by regulating the differentiation of M-MDSCs, and the percentage of M-MDSCs decreased by inhibiting the AMPK/mTOR signal pathway in vitro and in mice with pristane-induced lupus. This evidence concerns the gene MTOR and systemic lupus erythematosus.